Denzil Bernard
Healthwise(US)
Publications by Year
Research Areas
Cancer-related Molecular Pathways, Ubiquitin and proteasome pathways, Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, Protein Degradation and Inhibitors
Most-Cited Works
- → Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition(2008)652 cited
- → Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment(2014)445 cited
- → SAR405838: An Optimized Inhibitor of MDM2–p53 Interaction That Induces Complete and Durable Tumor Regression(2014)336 cited
- → Targeting the MDM2–p53 Protein–Protein Interaction for New Cancer Therapy: Progress and Challenges(2017)312 cited
- → A Potent Small-Molecule Inhibitor of the MDM2–p53 Interaction (MI-888) Achieved Complete and Durable Tumor Regression in Mice(2013)294 cited
- → Diastereomeric Spirooxindoles as Highly Potent and Efficacious MDM2 Inhibitors(2013)228 cited
- → High-Affinity, Small-Molecule Peptidomimetic Inhibitors of MLL1/WDR5 Protein–Protein Interaction(2012)210 cited
- → Discovery of 4-((3′R,4′S,5′R)-6″-Chloro-4′-(3-chloro-2-fluorophenyl)-1′-ethyl-2″-oxodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indoline]-5′-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development(2017)194 cited
- → Activating STAT6 mutations in follicular lymphoma(2014)143 cited
- → AI is a viable alternative to high throughput screening: a 318-target study(2024)114 cited